Sorted By Test Name - Mayo Medical Laboratories

MOLPS
89270
appetite, tachycardia, tachypnea, blindness, and coma. These symptoms can be corrected by introducing
molybdenum supplementation.(3) Molybdenum cofactor disease is a severe genetic disorder which is due
to defective mutations in the MOCS1, MOCS2, and GEPH genes. Molybdenum toxicity is rare and
usually related to molybdenum mining exposure; however it has been observed in cases of intake >400
mcg/day. Molybdenum interferes with copper uptake; molybdenum toxicity is predominantly due to
copper deficiency (hypochromic anemia and neutropenia) and inhibition of xanthine oxidase (uric acid
accumulation). Urine molybdenum concentrations are likely to be increased above the reference range in
patients with metallic joint prosthesis. Prosthetic devices produced by Zimmer Company and Johnson &
Johnson typically are made of aluminum, vanadium, and titanium. Prosthetic devices produced by Depuy
Company, Dow Corning, Howmedica, LCS, PCA, Osteonics, Richards Company, Tricon, and Whiteside
typically are made of chromium, cobalt, and molybdenum. This list of products is incomplete, and these
products change occasionally; see prosthesis product information for each device for composition
details.(4-5)
Useful For: Monitoring of parenteral nutrition Monitoring metallic prosthetic implant wear As an
indicator of molybdenum cofactor disease
Interpretation: Molybdenum excretion rates are variable and related to dietary intake. Evaluation of
124 healthy adults by Mayo Clinic suggested a reference range of 6 mcg/L to 190 mcg/L. The National
Health and Nutrition Examination Survey (NHANES) study reported urine molybdenum ranged from 20
mcg/L to 180 mcg/L. (Note: NHANES also reported excretion per gram of creatine as 40 mcg/gm to 100
mcg/gm creatinine in adults and 70 mcg/gm to 240 mcg/gm creatinine in children.) Prosthesis wear is
known to result in increased circulating concentration of metal ions.(5-7) No increase (6-190 mcg/L) in
urine molybdenum concentration is evident with a prosthetic device in good condition. Urine
concentrations >200 mcg/L in a patient with molybdenum-based implant suggest significant prosthesis
wear. Increased urine trace element concentrations in the absence of corroborating clinical information do
not independently predict prosthesis wear or failure. Urine molybdenum 400 mcg/day.
Molybdenum interferes with copper uptake; molybdenum toxicity is predominantly due to copper
deficiency (hypochromic anemia and neutropenia) and inhibition of xanthine oxidase (uric acid
Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 1224